📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
CRISIL Reaffirms Anupam Rasayan’s 'A+' Rating; Removes Negative Watch on ₹1369.82 Cr Debt
CRISIL has reaffirmed Anupam Rasayan's long-term rating at 'CRISIL A+/Stable' and removed it from 'Rating Watch with Negative Implications'. This resolution follows the successful integration of Tanfac Industries and a demonstrated improvement in the working capital cycle, with inventory days dropping from 270 to 210. The company maintained steady revenue of ₹1,101 crore in 9M FY24 with strong EBITDA margins of 27-28%. The stable outlook reflects the company's established market position and long-term contracts with global agrochemical and fluorochemical players.
Key Highlights
CRISIL reaffirmed Long-Term rating at 'A+/Stable' and Short-Term at 'A1' for ₹1369.82 crore bank facilities.
Removed 'Rating Watch with Negative Implications' following the successful acquisition and integration of Tanfac Industries.
Inventory days significantly improved to 210 days from 270 days, easing working capital pressure.
Reported 9M FY24 revenue of ₹1,101 crore with healthy operating margins sustained at 27-28%.
Net debt to EBITDA ratio is expected to remain manageable between 2.5x to 3.0x in the medium term.
💼 Action for Investors
The removal of the negative watch indicates reduced financial risk and successful deleveraging post-acquisition. Investors should view this as a sign of operational stability, though they should continue to monitor the working capital cycle and global demand for specialty chemicals.
Loading analysis...
Anupam Rasayan Completes $150 Million Acquisition of US-based Jayhawk Fine Chemicals
Anupam Rasayan has successfully completed the 100% acquisition of Jayhawk Fine Chemicals Corporation for approximately $150 million. The acquisition is financed through $129 million from Oaktree affiliate Altis XII and $21 million from Axis Bank, making it EPS accretive upon consolidation. Jayhawk, a US-based specialty chemical firm, provides high-performance materials to sectors like semiconductors and aerospace, with 65% of its revenue coming from these high-growth areas. This move significantly expands Anupam's global footprint and integrates its operations with Tanfac Industries for enhanced synergies.
Key Highlights
Acquisition of 100% equity stake in Jayhawk Fine Chemicals for a total consideration of ~$150 million.
Financing structure includes $129 million from Oaktree affiliate and $21 million debt from Axis Bank.
Jayhawk generates ~65% of revenue from performance materials serving electronics, energy, and aerospace sectors.
The transaction is expected to be immediately EPS accretive and will be fully consolidated with Anupam Rasayan.
Strategic expansion into the U.S. market to manufacture key N-1 molecules for critical high-tech sectors.
💼 Action for Investors
Investors should look favorably on this acquisition as it diversifies revenue streams into high-margin US tech sectors and is EPS accretive. Monitor the integration with Tanfac Industries and the impact on operating margins in the coming quarters.
Loading analysis...
Anupam Rasayan Completes Acquisition of Monitchem Kansas Sarl and Jayhawk Fine Chemicals
Anupam Rasayan India Limited has successfully completed the acquisition of Monitchem Kansas S.à r.l. and its subsidiaries, including the US-based Jayhawk Fine Chemicals Corporation. The transaction was finalized on February 27, 2026, through its wholly-owned subsidiary, Doriath S.à r.l. This strategic move, which follows an agreement signed in December 2025, significantly expands the company's global footprint and manufacturing capabilities in the specialty chemicals sector. The integration of these assets is expected to provide a strong platform for growth in the North American market.
Key Highlights
Completion of the acquisition of Monitchem Kansas S.à r.l. and three subsidiaries on February 27, 2026.
Acquired entities include Kansas HoldCo Inc., Kansas HoldCo 1, Inc., and Jayhawk Fine Chemicals Corporation.
The transaction was executed via Doriath S.à r.l., a wholly-owned subsidiary of Anupam Rasayan.
The deal follows the initial Sale and Purchase Agreement (SPA) executed on December 9, 2025.
Strategic expansion into the US market through the inclusion of Jayhawk Fine Chemicals.
💼 Action for Investors
Investors should view this as a positive growth milestone that enhances the company's global scale; monitor upcoming earnings for the financial consolidation impact of these new entities.
Loading analysis...
Anupam Rasayan Secures USD 30 Million ECB Facility for Monitchem Kansas Acquisition
Anupam Rasayan has executed a facility agreement to raise USD 30 million through External Commercial Borrowing (ECB) from Axis Bank and other syndicated lenders. The proceeds are specifically earmarked to partially finance the acquisition of Monitchem Kansas S.à r.l. and associated costs. The loan is secured by a pari passu charge on the company's movable and immovable fixed assets and is effective from February 19, 2026. This financing follows recent regulatory amendments by the RBI regarding foreign exchange management.
Key Highlights
Secured a USD 30 million (approx. ₹250 Cr) ECB facility from Axis Bank IBU GIFT City and syndicated lenders.
Funds will be utilized for the acquisition of Monitchem Kansas S.à r.l. and associated intragroup loan receivables.
Loan is secured by first ranking pari passu charge on movable fixed assets and identified immovable properties.
The facility became effective on February 19, 2026, following compliance with RBI's 2026 Foreign Exchange Management amendments.
Company corrected previous disclosure dates for the Share Subscription Agreement to February 14, 2026.
💼 Action for Investors
Investors should view this as a positive step toward completing a strategic acquisition, though they should monitor the company's debt-to-equity ratio post-drawdown. Watch for further updates on the completion of the Monitchem Kansas acquisition and its expected contribution to earnings.
Loading analysis...
Anupam Rasayan Q3 FY26 PAT Up 12% to ₹61 Cr; 9M Revenue Surges 84% to ₹1,730 Cr
Anupam Rasayan reported a robust 84% YoY growth in 9M FY26 revenue reaching ₹1,730 crores, driven by the scale-up of commercial molecules and improved capacity utilization. The company's PAT for the nine-month period rose 71% to ₹166 crores, while Q3 FY26 PAT grew 12% YoY to ₹61 crores. A significant strategic move was the announcement of the 100% acquisition of US-based Jayhawk Fine Chemicals, which is expected to be EPS accretive immediately upon closing. Segmental performance was strong, with the Performance Material vertical growing 245% YoY and Pharma growing 85% YoY during the first nine months.
Key Highlights
9M FY26 consolidated revenue grew 84% YoY to ₹1,730 crores with EBITDA margins at 23%.
Performance Material segment revenue surged 245% YoY in 9M FY26, contributing 17% to total sales.
Pharma segment delivered 85% YoY growth in 9M FY26, now representing 19% of the revenue mix.
Signed definitive agreement to acquire 100% of Jayhawk Fine Chemicals (USA) to establish a direct manufacturing presence in North America.
LOIs and contracts contributed over ₹250 crores to the revenue during the nine-month period.
💼 Action for Investors
Investors should monitor the integration of the Jayhawk acquisition and the continued ramp-up of the high-growth Performance Material and Pharma segments. The company's successful backward integration through Tanfac and expansion into the US market strengthens its long-term competitive position.
Loading analysis...
Anupam Rasayan Executes $150M Corporate Guarantee and $30M ECB for Global Acquisition
Anupam Rasayan India Limited has finalized a series of financial agreements to fund its overseas acquisition of Monitchem Kansas S.à r.l. through its subsidiary Doriath. The company has executed corporate guarantees totaling USD 150 million and secured a USD 30 million External Commercial Borrowing (ECB) from Axis Bank. To back these facilities, the company has pledged its 100% stake in Doriath and entered a non-disposal undertaking for its 25.80% stake in Tanfac Industries Limited. This structured financing facilitates the strategic acquisition while significantly increasing the company's contingent liabilities and asset encumbrance.
Key Highlights
Executed corporate guarantees aggregating to USD 150 million to support credit facilities for overseas subsidiaries.
Secured a USD 30 million External Commercial Borrowing (ECB) from Axis Bank for the parent company.
Wholly-owned subsidiary Doriath availed a USD 20 million credit facility from Altis XII Pte. Ltd. for acquisition purposes.
Provided a non-disposal undertaking for the company's 25.80% shareholding in Tanfac Industries Limited as security.
Acquisition involves 100% of Monitchem Kansas S.à r.l. and associated intragroup loan receivables.
💼 Action for Investors
Investors should monitor the revenue and margin contribution from the newly acquired Monitchem Kansas to ensure it offsets the increased debt servicing costs. The significant encumbrance of assets and the Tanfac stake undertaking are key risk factors to watch in the consolidated balance sheet.
Loading analysis...
Anupam Rasayan Secures $50M Financing and $150M Guarantees for Monitchem Kansas Acquisition
Anupam Rasayan has executed definitive agreements to fund the acquisition of Monitchem Kansas S.à r.l. through its subsidiary Doriath. The financing structure includes a $30 million External Commercial Borrowing (ECB) for the parent company and a $20 million credit facility for Doriath. Additionally, Batam S.à r.l. will invest $110 million into Doriath to facilitate the transaction. To secure these facilities, Anupam Rasayan has provided corporate guarantees totaling $150 million and a non-disposal undertaking for its 25.8% stake in Tanfac Industries.
Key Highlights
Secured $30 million ECB from Axis Bank and $20 million credit facility for subsidiary Doriath.
Batam S.à r.l. to invest $110 million into Doriath to fund the 100% acquisition of Monitchem Kansas.
Company provided corporate guarantees aggregating to $150 million to secure the credit facilities.
Security includes a non-disposal undertaking of the company's 25.8% shareholding in Tanfac Industries Limited.
Acquisition of 100% stake in Doriath and 15% stake in Batam completed/in-process to facilitate the deal.
💼 Action for Investors
Investors should view this as a major strategic expansion, though they should monitor the impact of the $150 million guarantee and increased debt on the balance sheet. The integration of Monitchem Kansas will be the key driver for future earnings growth.
Loading analysis...
Anupam Rasayan Q3 Revenue Up 31%; Announces $150M Acquisition of US-based Jayhawk Fine Chemicals
Anupam Rasayan reported a robust 9M FY26 performance with consolidated revenue growing 84% YoY to ₹17,297 million and PAT increasing 71% to ₹1,662 million. A major strategic highlight is the definitive agreement to acquire US-based Jayhawk Fine Chemicals for an enterprise value of $134 million, which is expected to significantly enhance its global footprint and performance materials portfolio. While Q3 FY26 revenue grew 31% YoY to ₹5,124 million, consolidated EBITDA margins compressed to 25% from 31% in the year-ago period. The acquisition will be funded through a mix of internal accruals, debt, and quasi-equity, creating a pro-forma entity with approximately $243 million in revenue.
Key Highlights
9M FY26 consolidated revenue surged 84% YoY to ₹17,297 Mn, with PAT rising 71% to ₹1,662 Mn.
Q3 FY26 standalone PAT witnessed a 150% YoY increase to ₹479 Mn on the back of 89% standalone revenue growth.
Acquisition of Jayhawk Fine Chemicals (USA) for a total consideration of ~$150M, adding ~$78M in annual revenue.
Consolidated EBITDA for 9M FY26 stood at ₹4,024 Mn, representing a 53% YoY growth despite margin pressure.
Life Science related specialty chemicals continue to dominate the business mix, contributing 83% of total revenues.
💼 Action for Investors
Investors should focus on the strategic benefits of the Jayhawk acquisition which provides direct access to North American innovators and high-value performance materials. While the growth momentum is strong, monitoring the stabilization of EBITDA margins and the successful integration of the US acquisition will be key for long-term value.
Loading analysis...
Anupam Rasayan Q3FY26 Revenue Jumps 33% to ₹5,145 Mn; Announces US Acquisition
Anupam Rasayan reported a robust 33% YoY increase in revenue for Q3FY26, reaching ₹5,145 million. Profit After Tax (PAT) grew by 12% YoY to ₹606 million, while EBITDA margins stood at 25.20%. A significant strategic development is the definitive agreement to acquire Jayhawk Fine Chemicals in the USA, aimed at strengthening their presence in North American regulated markets. The company continues to show strong momentum in its custom synthesis and specialty chemicals business with 9M FY26 revenue reaching ₹17,297 million.
Key Highlights
Total Revenue for Q3FY26 grew 33% YoY to ₹5,145 million compared to ₹3,866 million in Q3FY25.
EBITDA increased by 7% YoY to ₹1,296 million with an EBITDA margin of 25.20%.
Profit After Tax (PAT) rose 12% YoY to ₹606 million from ₹542 million in the previous year.
9M FY26 consolidated revenue reached ₹17,297 million with EBITDA of ₹4,024 million.
Signed definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States.
💼 Action for Investors
The strong top-line growth and strategic US acquisition signal positive long-term expansion; however, investors should monitor EBITDA margin trends which grew slower than revenue. Hold for long-term gains as the company integrates the Jayhawk acquisition into its global platform.
Loading analysis...
Anupam Rasayan Q3 Standalone PAT Jumps 150% YoY to ₹47.9 Cr; Revenue Up 89% YoY
Anupam Rasayan reported a strong year-on-year performance for Q3 FY26, with standalone revenue from operations rising 89% to ₹401.37 crore compared to ₹212.09 crore in the same quarter last year. Standalone Profit After Tax (PAT) surged by 150% YoY to ₹47.92 crore, although revenue saw a sequential decline from Q2 FY26. The company successfully utilized ₹277.5 crore from a preferential allotment for debt repayment and general corporate purposes. For the nine-month period, the company's performance shows a massive recovery with PAT reaching ₹119.01 crore compared to ₹34.58 crore in the previous year.
Key Highlights
Standalone Revenue from Operations grew 89.2% YoY to ₹4,013.67 million in Q3 FY26.
Standalone Net Profit (PAT) increased by 150.4% YoY to ₹479.19 million.
9M FY26 Standalone PAT stands at ₹1,190.13 million, a 244% increase over 9M FY25.
Finance costs for 9M FY26 rose to ₹1,020.65 million from ₹776.81 million YoY.
Successfully raised and utilized ₹2,775 million via preferential allotment for debt reduction by December 31, 2025.
💼 Action for Investors
Investors should focus on the significant year-on-year recovery and the positive impact of debt reduction on the balance sheet. Monitor the sequential revenue volatility and the performance of the Tanfac Industries associate for consolidated growth trends.
Loading analysis...
Anupam Rasayan Denies Rumors of Stake Acquisition in Bliss GVS Pharma
Anupam Rasayan India Limited has officially clarified media reports regarding a rumored stake acquisition in Bliss GVS Pharma Ltd. The company stated that no such material event or information exists that requires disclosure under SEBI Regulation 30. Management has chosen not to comment further on the speculation while emphasizing their ongoing compliance with disclosure norms. This clarification was issued on February 13, 2026, to address market rumors and prevent misinformation.
Key Highlights
Official denial of media reports regarding a potential stake purchase in Bliss GVS Pharma.
Clarification provided under SEBI (LODR) Regulation 30(11) on February 13, 2026.
Company maintains there is no undisclosed material information at this time.
Management refuses to comment on further market speculation appearing in electronic media.
💼 Action for Investors
Investors should treat the acquisition reports as unverified speculation and avoid making trading decisions based on these rumors. Monitor official company filings for any actual strategic developments or future M&A activity.
Loading analysis...
Anupam Rasayan Finalizes Acquisition Structure; Secures USD 50 Million Financing
Anupam Rasayan has advanced its global expansion strategy by acquiring 100% of Doriath S.à r.l. and 15% of Batam S.à r.l. to facilitate the takeover of the Monitchem Kansas group, including Jayhawk Fine Chemicals. To fund this, the company has secured a USD 30 million ECB facility from Axis Bank and a USD 20 million credit facility for its subsidiary Doriath. This follows a previously approved shareholder limit of Rs. 4,500 crores for investments and guarantees. The company is leveraging its assets and shares in Tanfac Industries as security for these facilities.
Key Highlights
Completed 100% acquisition of Doriath S.à r.l. on February 10, 2026, to serve as an acquisition vehicle.
Secured USD 30 million External Commercial Borrowing (ECB) from Axis Bank, IBU GIFT City.
Subsidiary Doriath to avail USD 20 million credit facility from Altis XII Pte. Ltd. for the target acquisition.
Assigned rights to acquire Jayhawk Fine Chemicals Corporation and related entities to subsidiary Doriath.
Provided non-disposal undertakings for shares in Tanfac Industries Limited as part of the security package.
💼 Action for Investors
Investors should monitor the successful integration of Jayhawk Fine Chemicals and the impact of the USD 50 million debt on the company's balance sheet. The strategic move into the US market is a long-term positive for the specialty chemicals portfolio.
Loading analysis...
Anupam Rasayan Approves $50M Financing for Monitchem Kansas and Jayhawk Acquisition
Anupam Rasayan has finalized the financing and structural details for the acquisition of Monitchem Kansas S.à r.l and its subsidiaries, including Jayhawk Fine Chemicals. The company has secured a $30 million External Commercial Borrowing (ECB) from Axis Bank and a $20 million credit facility for its subsidiary, Doriath S.à r.l. These funds will be used to complete the international acquisition, with the board also approving corporate guarantees and asset charges to secure the debt. This follows a prior shareholder mandate allowing for investments and guarantees up to Rs. 4,500 crores.
Key Highlights
Acquisition of 100% stake in Doriath S.à r.l. and 15% in Batam S.à r.l. to facilitate the global transaction structure.
Secured a $30 million ECB facility from Axis Bank and a $20 million credit facility from Altis XII Pte. Ltd.
Assigned rights to acquire Monitchem Kansas S.à r.l and Jayhawk Fine Chemicals Corporation to subsidiary Doriath.
Approved creation of security via hypothecation of movable assets and a non-disposal undertaking of shares in Tanfac Industries Limited.
The board ratified the completion of the Doriath acquisition as of February 10, 2026.
💼 Action for Investors
Investors should view this as a significant step in the company's global expansion into specialized fine chemicals, though they should monitor the impact of the $50 million debt on the balance sheet. Watch for future updates on the operational integration of Jayhawk Fine Chemicals and its contribution to consolidated margins.
Loading analysis...
Anupam Rasayan Shareholders Approve ₹4,500 Crore Borrowing and Investment Limits
Shareholders of Anupam Rasayan India Limited have passed three key special resolutions via postal ballot with over 99.6% majority. The company has secured approval to increase its borrowing limits to ₹4,500 Crores and has similarly increased its limits for investments, loans, and guarantees to ₹4,500 Crores. Additionally, the board is now authorized to mortgage or charge company assets to secure these borrowings. This significant increase in financial headroom suggests the company is positioning itself for major capital expenditure or strategic acquisitions.
Key Highlights
Approved increase in overall borrowing limits to ₹4,500 Crores under Section 180(1)(c).
Authorized investment, loan, and guarantee limits up to ₹4,500 Crores under Section 186.
Empowered the Board to mortgage or dispose of undertakings to secure borrowings within the new limits.
All resolutions passed with overwhelming majority, receiving over 99.6% of votes in favor.
The new limits supersede all previous resolutions regarding borrowing and investment caps.
💼 Action for Investors
Investors should view this as a signal of upcoming expansion or M&A activity, though they should monitor the actual debt levels and the quality of future investments. Keep a close watch on the company's debt-to-equity ratio as these new limits are utilized.
Loading analysis...
Anupam Rasayan Shareholders Approve Increased Borrowing and Investment Limits
Anupam Rasayan India Limited has successfully passed three key special resolutions via postal ballot with overwhelming shareholder support. The resolutions grant the company authority to increase its overall borrowing limits and to sell, lease, or mortgage company undertakings. Additionally, shareholders approved exceeding statutory limits for investments, loans, and guarantees under Section 186 of the Companies Act. These approvals provide the management with significant financial flexibility to fund future growth and strategic initiatives.
Key Highlights
Resolution to increase overall borrowing limits passed with 99.97% votes in favor.
Approval to sell, lease, or mortgage company undertakings received 99.97% shareholder support.
Authority to make investments and provide guarantees beyond Section 186 limits passed with 99.67% approval.
Total valid votes cast across resolutions represented approximately 73.08% of the total equity shares.
💼 Action for Investors
Investors should monitor the company's debt-to-equity ratio and upcoming capital expenditure plans, as these approvals signal potential large-scale expansion or acquisitions. The high approval rate indicates strong shareholder confidence in the management's strategic financial planning.
Loading analysis...
Anupam Rasayan Acquires US-based Jayhawk Fine Chemicals for $150 Million
Anupam Rasayan has signed a definitive agreement to acquire 100% of US-based Jayhawk Fine Chemicals for an enterprise value of $134 million, representing a 9x CY24 EBITDA multiple. Jayhawk reported revenues of $78 million in CY24 with a 19% EBITDA margin, specializing in high-value performance materials and life sciences. The deal is funded via $40 million from internal accruals/debt and $110 million from a global investment firm through non-voting shares. This strategic acquisition establishes a direct US manufacturing presence and is expected to be EPS-accretive from day one.
Key Highlights
Acquisition of Jayhawk Fine Chemicals for a total consideration of $150 million, including $16 million cash on balance sheet.
Jayhawk generated $78 million in revenue and ~19% EBITDA margin in CY24, serving semiconductor, EV, and aviation sectors.
Combined entity pro-forma financials show revenue of approximately $243 million and EBITDA of $61 million.
Funding structure involves $110 million from an external investment firm via Class B non-voting shares to maintain full operational control.
Strategic alignment with the US Biosecure Act to capture CDMO demand shifting away from restricted geographies.
💼 Action for Investors
Investors should view this as a significant growth catalyst that provides geographic de-risking and entry into high-margin US CDMO markets. Monitor the integration process and the realization of cross-selling synergies between the Indian and US entities.
Loading analysis...
Anupam Rasayan Credit Rating Placed on Watch with Negative Implications for INR 11,961M Debt
India Ratings and Research (Ind-Ra) has placed Anupam Rasayan's long-term issuer rating of 'IND AA-' on 'Rating Watch with Negative Implications'. This status also applies to the company's bank loan facilities totaling INR 11,961 million, including the short-term 'IND A1+' rating. While the current ratings reflect high creditworthiness, the negative watch indicates a potential downgrade in the near future. Investors should monitor the company's leverage and operational cash flows which likely triggered this cautionary stance.
Key Highlights
India Ratings and Research (Ind-Ra) assigned 'Rating Watch with Negative Implications' to all rated instruments.
Long-term issuer rating currently stands at 'IND AA-' but is subject to potential downward revision.
Bank loan facilities worth INR 11,961 million are covered under this rating action.
Short-term rating for bank facilities is maintained at 'IND A1+' with negative implications watch.
The rating action was officially disclosed to exchanges on December 18, 2025.
💼 Action for Investors
Investors should remain cautious as a 'Negative Watch' often signals rising financial risk or deteriorating debt-service metrics. Monitor the company's upcoming financial results for any signs of margin contraction or increased debt levels.
Loading analysis...
Anupam Rasayan Credit Rating Placed on Negative Watch for INR 11,961 Million Facilities
India Ratings and Research (Ind-Ra) has placed Anupam Rasayan India Limited's long-term issuer rating of 'IND AA-' on 'Rating Watch with Negative Implications'. This status also applies to the company's bank loan facilities totaling INR 11,961 million, including short-term ratings of 'IND A1+'. A negative watch typically signals a potential downgrade in the near future, often due to deteriorating financial metrics or operational headwinds. Investors should be concerned about the possibility of increased borrowing costs if a downgrade occurs.
Key Highlights
Long-term issuer rating assigned as 'IND AA-' with Rating Watch with Negative Implications
Short-term rating for bank facilities assigned as 'IND A1+' with Rating Watch with Negative Implications
Rating action covers total bank loan facilities amounting to INR 11,961 million
The update was issued by India Ratings and Research (Ind-Ra) on December 18, 2025
💼 Action for Investors
Investors should monitor the company's debt-to-equity and interest coverage ratios closely, as a formal downgrade could lead to higher financing costs. It is advisable to wait for the detailed rating rationale to understand the specific triggers behind the negative watch.
Loading analysis...
Anupam Rasayan Updates on US Acquisition via Investor Call Recording
Anupam Rasayan India Limited has released the audio recording of its investor call held on December 15, 2025. The call was specifically dedicated to providing updates on the company's US acquisition plans. This move is part of the company's broader strategy to enhance its presence in international markets. Investors are encouraged to review the recording on the company's website for detailed management commentary on the transaction.
Key Highlights
Investor call conducted on December 15, 2025, at 04:30 p.m. IST
Focused on providing updates regarding a strategic US acquisition
Audio recording link made available to the public on December 16, 2025
💼 Action for Investors
Investors should analyze the recording to understand the financial implications and strategic rationale of the US acquisition. Pay close attention to the acquisition cost and expected contribution to the bottom line.
Loading analysis...
Anupam Rasayan Investor Call on US Acquisition Update on Dec 15, 2025
Anupam Rasayan India Limited is holding an investor call on December 15, 2025, at 4:30 p.m. IST to discuss the US Acquisition Update. The call will be hosted by Investec Capital Services. Key management personnel, including Anand Desai (MD), Gopal Agarwal (CEO), Vishal Thakkar (Deputy CFO), and Ravish Chaudhary (Sr. Manager) will be present. Investors can join via the provided conference dial-in numbers or the express login link.
Key Highlights
Investor call scheduled for December 15, 2025, at 4:30 p.m. IST
Call is to discuss the US Acquisition Update
Primary Universal Number for the conference call is +91 22 7195 0000
International Toll-Free Number for USA is 18667462133
💼 Action for Investors
Investors interested in Anupam Rasayan's US acquisition should attend the investor call to gain insights. Monitor company updates and analyst reports following the call for further information.